Table 1 Summary of baseline patient characteristics.
From: A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Characteristic | All LXS196 QD patients n = 38 | All LXS196 BID patients n = 30 | LXS196 300 mg BID (RDE) patients n = 18 | All LXS196 patients N = 68 | |
|---|---|---|---|---|---|
Median age, years (range) | 55 (26–76) | 57 (33–78) | 56.5 (38–76) | 56 (26–78) | |
Sex, n (%) | Male | 22 (57.9) | 14 (46.7) | 7 (38.9) | 36 (52.9) |
Female | 16 (42.1) | 16 (53.3) | 11 (61.1) | 32 (47.1) | |
ECOG performance status, n (%) | 0 | 37 (97.4) | 25 (83.3) | 14 (77.8) | 62 (91.2) |
1 | 1 (2.6) | 5 (16.7) | 4 (22.2) | 6 (8.8) | |
Lactate dehydrogenase, n (%) | >ULN | 23 (60.5) | 15 (50.0) | 8 (44.4) | 38 (55.9) |
≤ULN | 15 (39.5) | 15 (50.0) | 10 (55.6) | 30 (44.1) | |
Prior systemic therapies, n (%) | 0 | 3 (7.9) | 6 (20.0) | 6 (33.3) | 9 (13.2) |
1 | 19 (50.0) | 18 (60.0) | 9 (50.0) | 37 (54.4) | |
2 | 12 (31.6) | 2 (6.7) | 2 (11.1) | 14 (20.6) | |
>2 | 4 (10.5) | 4 (13.3) | 1 (5.6) | 8 (11.8) | |
Prior immunotherapeutic agent, n (%) | All | 22 (57.9) | 14 (46.7) | 4 (22.2) | 36 (52.9) |
Ipilimumab | 8 (21.1) | 4 (13.3) | 0 | 12 (17.6) | |
Nivolumab | 8 (21.1) | 4 (13.3) | 0 | 12 (17.6) | |
Pembrolizumab | 11 (28.9) | 10 (33.3) | 4 (22.2) | 21 (30.9) | |
Tebentafusp | 0 | 0 | 0 | 0 | |
Sites of metastases, n (%) | Liver only | 13 (34.2) | 14 (46.7) | 9 (50.0) | 27 (39.7) |
Liver + other | 20 (52.6) | 13 (43.3) | 7 (38.9) | 33 (48.5) | |
Other | 5 (13.2) | 3 (10.0) | 2 (11.1) | 8 (11.8) | |
Maximum target lesion diameter (mm) | Median (range) | 39 (11–126) | 35.5 (11–201) | 40 (11–201) | 36 (11–201) |
